News Detail
Maryland, 19 Dec 2017: The U.S. Food and Drug Administration (FDA) is requiring a new class warning and other safety measures for all gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI) concerning gadolinium remaining in patients’ bodies, including......
View Details
Source : US FDA Safety Anouncement
Related News
- Coronil controversy: IMA asks Patanjali to furnish documents (26-02-2021)
- Govt working to reduce regulatory compliance burden on pharma sector: Sadananda Gowda (26-02-2021)
- IPC signs MoU with BPC for knowledge sharing on pharmacopoeial standards (26-02-2021)
- IIT-Madras researchers identify alternative source for anti-cancer drug Camptothecin (26-02-2021)
- Tests on kids: Expert panel asks Bharat Biotech to submit Covaxin efficacy data first (26-02-2021)
- Health Authorities Silent as the Medical Community Fights Against Patanjali’s CORONIL (25-02-2021)
- US FDA says single-dose shot from J&J prevents severe COVID (25-02-2021)
- SC imposes Rs 5 crore fine on medical college in Unnao for violating MCI regulations (25-02-2021)
- AP: Counterfeit drugs found in Bhimavaram (24-02-2021)
- Cabinet Approves Production Linked Incentive Scheme For Pharmaceuticals (24-02-2021)